HC Wainwright Has Positive Estimate for RMTI Q3 Earnings

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities research analysts at HC Wainwright lifted their Q3 2027 earnings estimates for Rockwell Medical in a research note issued on Thursday, July 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn $0.13 per share for the quarter, up from their previous forecast of $0.10. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q4 2027 earnings at $0.15 EPS.

Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Thursday, May 7th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.30). The company had revenue of $17.34 million for the quarter, compared to the consensus estimate of $17.95 million. Rockwell Medical had a negative return on equity of 15.41% and a negative net margin of 7.98%.

RMTI has been the subject of a number of other research reports. Weiss Ratings cut Rockwell Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 15th. Wall Street Zen upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Rockwell Medical currently has an average rating of “Hold” and a consensus price target of $20.00.

Rockwell Medical Stock Up 2.3%

Rockwell Medical stock opened at $5.76 on Friday. The stock has a market cap of $22.75 million, a P/E ratio of -3.84 and a beta of 1.61. The company has a quick ratio of 3.43, a current ratio of 3.74 and a debt-to-equity ratio of 0.23. Rockwell Medical has a twelve month low of $4.89 and a twelve month high of $21.00. The company’s 50-day moving average price is $7.06 and its two-hundred day moving average price is $8.72.

Hedge Funds Weigh In On Rockwell Medical

Several institutional investors and hedge funds have recently modified their holdings of RMTI. Corsair Capital Management L.P. bought a new position in Rockwell Medical during the first quarter worth about $45,000. XTX Topco Ltd boosted its holdings in Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after purchasing an additional 46,029 shares during the period. Jane Street Group LLC bought a new stake in Rockwell Medical in the 4th quarter valued at about $84,000. Geode Capital Management LLC grew its position in shares of Rockwell Medical by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock worth $304,000 after purchasing an additional 41,668 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in shares of Rockwell Medical by 36.5% during the 1st quarter. Renaissance Technologies LLC now owns 639,120 shares of the company’s stock worth $571,000 after purchasing an additional 170,800 shares in the last quarter. 23.31% of the stock is currently owned by institutional investors and hedge funds.

About Rockwell Medical

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.